Article

Rapamycin safe for treating DME, finds phase I trial

A phase I trial of rapamycin (Sirolimus, Wyeth) indicated that the drug is safe and has biologic activity against diabetic macular edema (DME), according to Mark Blumenkranz, MD.

A phase I trial of rapamycin (Sirolimus, Wyeth) indicated thatthe drug is safe and has biologic activity against diabeticmacular edema (DME), according to Mark Blumenkranz, MD.

A total of 50 patients with DME were included in thisprospective, randomized, dose-escalation trial. The patientsreceived either one intravitreal injection or one subconjunctivalinjection. For the 25 patients in the intravitreal group, thedoses ranged from 44 to 352 µg, and for the 25 patients in thesubconjunctival group the doses ranged from 220 to 1,760µg. The baseline demographics of the two groups weresimilar.

The investigators found no significant systemic exposure torapamycin. Dr. Blumenkranz reported that the drug was relativelywell tolerated and there was no dose-limiting toxicityencountered. There were five serious adverse events (vitreoushemorrhages and epiretinal membranes), none of which wasconsidered by the investigators to be related to the drugitself.

"Importantly, there was no progression in cataract and there wasno increase in IOP levels aside from the transient IOP increasesthat occur immediately following the injection," Dr. Blumenkranzsaid.

Both routes of administration were found to be effective. Thevisual acuity increased a mean of five letters in both groups byday 90 after treatment that was accompanied by a decrease in themacular thickness seen on optical coherence tomography scanning.The group that received the subconjunctival injection hadslightly better efficacy; with the two lowest doses (220 and 440µg), the investigators found a mean visual acuity increaseof about six letters, according to Dr. Blumenkranz.

"The formulation of rapamycin designed for ocular use, bothintraocularly and subconjunctivally, was judged to be safe as theresult of the absence of serious adverse events related to thedrug," Dr. Blumenkranz said. "There appeared to be preliminaryefficacy signals, although this study was not designed to showefficacy. The drug is moving into a phase II trial for patientswith DME and age-related macular degeneration."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.